The attenuated or non-pathogenic live vectors have been evolved specifically to deliver DNA lnto cells as efficient delivery tools in gene therapy. Recently, a non-pathogenic protozoan, Leishmania tarentolae (Ltar) has attracted a great attention. ln current study, we used Leishmania expression system (LEXSY) for stable expression of HPV16 E7 linked to different mini-chaperones [N-/C-terminal of gp96l and compared their immunogenicity and protective effects in CS7BU6 mice against TC-1 challenge. TC-1 murine model is primary C57BU6 mice Jung epithelial cells co-transformed with HPV16 E6, HPV16 E7 and ras oncogenes. Our results showed that subcutaneous administration of mice with both the recombinant L.tar-E7-NT
lntroduction
Infection with human papillomavirus (HPV), parlicularly HPV16, can result in cervical cancer (Bolhassani et al., 2009; Seo et al., 2009) . Several therapeutic vaccines that target the HPV E6 and E7 proteins have been developed over the past years (Kanodia et al., 2008) . Various forms of vaccines such as vector-based vaccines, tumor-based vaccines, DNA-based vaccines and protein/peptide-based vaccines have been described in experimental systems targeting HPVI6 E6 andl or E7 proteins (Bolhassani et al., 2009) . Recently, live recombinant vectors are centrat in the development of new vaccine strategies. Biological carriers are viruses or bacteria, which were naturally evolved to infect cells and transfer their genetic materials into the host cells (EI-Aneed, 2004) . Viruses used in gene therapy are modified in the laboratory to eliminate their pathogenicity and retain their high efficiency in gene transfer (EI-Aneed, 2004) . Intracellular bacteria (e.g. Listeria and Salmonella) as weil as viral vectors (e.g. Vaccinia, adenovirus) have been extensively used for vaccine development against HPV infection (Kanodia et al., 2008) . However, the use of bacterial or viral recombinant vectors s~quence (Lys-Asp-Giu-Leu), which is a retention/retrieval s Ign~) from the Golgi to the ER (Robert, 2003) . Several
Approximately 10 J.lg of the expression plasmids were digested with SwaJ restriction sites and the product was separated on a 0.8% agarose gel. The bands corresponding to the expected size was gel purified (QIAquick gel extraction kit) for electroporation.
Parasite growth and transfections tu~Jes indicated that immune activities of HSPs (e.g. Gp96)
resJde w'th' . . .
The L. tarento/ae strain (ATCC 30267) was grown at 26 °C in complete Ml99 medium (Bolhassani et al., 2011) . For transfection, 4 x 10 7 Iog-phase parasites re-suspended in ice-cold electroporation buffer (pH = 7.5) containing 8 pg of linearized pLEXSY-E7-NT-GFP or pLEXSY-E7-CT-GFP, stored on ice for 10 min and electroporated using Bio-Rad Gene Pulser Ecell under conditions of 500 J.IF, 450 V and pulse time "'5-6 ms. The electroporated promastigotes were plated on solid media containing 50 J.lg/ml of G418 (Bolhassani et al., 2011 ) . Clones were selected on Noble agar plates and further propagated in liquid M 199 10% medium in the absence of 0418. Expression of E7-NT-GFP and E7-CT-GFP proteins in promastigote stage of the recombinant Leishmania species was evaluated by Epifluorescent microscopy (Nikon, E200, ACT-1 software Japan) as weil as flow cytometry (BD: Becton Dickinson). ' h 1 m the1r N-or C-terminal fragments known as mimaperones (Biswas et al., 2006; ol~assani et al., 2008) . These potent regions of HSPs are mvolved in development of various vaccines including DNA-based vaccine and protein/peptide-based vaccine . Our previous study demonStrated that co-delivery of E7 + Gp96 as DNA/DNA and E7 + CT (gp96) as DNNprotein could be an effective approach to induce E7-specific immune responses as a potential vaccine candidate for cervical cancer .
In the present study, we have used a Leishmania expression vector (LEXSY), which can mediate high-level production of heterologous proteins both intracellularly and extracellularly (Bolhassani et al., 2011) . L tarentolae was transfected with the expression cassettes containing E7-NT (gp96) or E7-CT (gp96) genes fused to the green fluorescent protein (GFP) as a reporter gene in order to rapidly and sensitively quantify Leishmania promastigotes. We showed that expression cassettes including E7-NT (gp96)-GFP/E7-CT (gp96)-GFP genes integrale in Leishmania 18 S rRNA through homologous recombination. In continuation, the potential of two recombinant L tarentolae expressing E7-NT (gp96) and E7-CT (gp96) was evaluated to reduce HPVI6 E7-overexpressing tumors in C57BU6 mice model.
Materials and methods
Plasmid DNA constructs and preparation For the generation of E7-NT (gp96)-GFP-expressing plasmid [pLEXSY-E7-NT (gp96)-GFP], the E7-NT (gp96)-GFP gene was sub-cloned from pcDNA-E7-NT (gp96)-GFP (previously provided by our groups in Molecular Immunology and Vaccine Research Lab.) into the Bgni and Kpnl cloning sites of pLEXSY-neo2 expression vector (Jena bioscience). Furthermore, to make the E7-CT (gp96)-GFP-expressing plasmid [pLEXSY-E7-CT (gp96)-GFP], the E7-CT (gp96) gene was sub-cloned from pUC-E7-CT (gp96) into the Bgni and Kpnl cloning sites of pLEXSY-GFP expression vector. DNA constructs containing E7-NT-GFP and E7-CT-GFP were purified in large-scale using Midi-kit (Qiagen). The presence of the inserted genes was confirmed by PCR and restriction enzyme digestion as detected on gel Confirmation of E7-NT (gp96)-GFP or E7-cr (gp96)-GFP gene Integration by diagnostic PCR Integration of the linearized expression cassettes into the ssu locus was confirmed by diagnostic PCR using genomic DNA of wild type and transgenic strains of L. tarentolae as template. For this purpose, a primer pair including one primer hybridizing within the expression cassette and one primer hybridizing to a ssu sequence not present on the plasmid were used (Bolhassani et al., 2011) . Furthermore, additional diagnostic PCR was performed by specific primcrs for E7, GFP, E7-NT, NT-GFP, E7-CT and CT-GFP using genomic DNA of transgenic L. tarentolae.
RNA extraction and reverse-transcription PCR
RNA samples were extracted from promastigote form of wild type and transgenic parasites using RNeasy mini-kit (Qiagcn) according to the manufacturer's instructions. The cDNA synthesis was performed using Omniscript Reverse Transcriplase kit (Qiagen) from I pg of RNA (Bolhassani et al., 2011) . PCR analysis was performed to amplify E7-NT, NT-GFP, E7-CT and GFP undcr standard conditions.
Western blot analysis
Promastigote forms were harvested by centrifugation at 3000rpm for 10 min and washed in PBS IX (Bolhassani et al., 2011) . Sampies from both wild type and transgenic L tarentolae were separated by SOS-PAGE in a 12.5% (w/v) polyacrylamide gel. Western blot analyses were performed to confirm E7-er-GFP or E7-NT-GFP protein expression using anti-HPV16 E7 monoclonal antibody (I: 10 000 v/v, USBiological) or anti-GFP polyclanal antibody (1:5000 v/v; Acris antibodies GmbH) under standard procedures, respectively. The immunoreactive protein bands were visualized using peroxidase substrate named 3,3'-diaminobenzidine (DAB, Sigma, St. Louis, MO) (Bolhassani et al., 2011) .
Preparation of the recombinant proteins and Freezthaw parasites
For the production of recombinant E7, NT (gp96) and er (gp96) proteins, the bacterial cultures containing pQE-E7, pQE-NT (gp96) and pQE-CT (gp96) were grown to an optical density of 0.6-0.8 at 600 nm and protein expression was induced with 1 mM IPTG for 2 h at 37 oc. Protein samples were analyzed by SDS-PAGE in 12.5% (WN) polyacrylamide gel. The recombinant E7, er and NT proteins were purified by affinity chromatography using 6xHis-tag accord~ ing to the manufacturer's instructions (Qiagen) (Bolhassam et al., 2008) . In addition, the promastigotes of transgenic parasites were harvested from stationary phase cultures by centrifugation, washed two times with PBS and disrupted by 15 rounds of freezing and thawing. Protein concentrations were measured using BCA assay kit (Pierce, Rockford, IL) and kept at -70 °C prior to use.
Cells
TC-1 (ATCC number: CRL-2785) canceraus cell Jine (Ji et al., 1998) was cultured in complete RPMI 1640 . On the day of tumor challenge, TC-1 cells were harvested by trypsinization, counted and finally re-suspended in PBS.
Mice immunization
lobred C57BU6 female mice, 6-8 week old were obtained from the breeding stocks maintained at the Pasteur Institute of Iran. All anima1 procedures were performed according to approved protocols and in accordance with the recommendations for the proper use and care of Iabaratory animals. Five groups of 12 mice were selected. For priming, test groups were immunized subcutaneously (s.c.) at the footpad with 2 x 10 7 stationary-phase recombinant L tarentolae promastigotes expressing E7-CT-GFP (G1), E7-NT-GFP (G2) and E7-GFP (G3) proteins. The cont.rol groups (G4 & G5) were injected with L: tarentolae expressmg GFP and PBS, respectively. We cons1dered another con.trol group as untreated or Nai"ve mice (G6) (10 m1~e) for evaluation of antibody responses and protecuve effects. For boosting (3 weeks after priming), all groups 1-5 received the regimens similar to priming. Three weeks after booster, all groups subcutaneously received. 1 x 10 5 TC-1 cells on the right flank. Table 1 shows the reg1mens of each group.
Monitaring humoral immune response
Mice sera were collected from all groups before and 2 weeks after challenge. Pooled sera for each group were stored Drug Deliv, 2013; 20(3-4): 190-198 
TC-1 at -20°C. lgGl and IgG2a (1:1000, Southern biotechnology Association, USA) were rneasured using ELISA against recombinant (r) E7 (5 ).lg/ml), NT (gp96) (2.5 ).lg/ml), CT (gp96) ( 10 ).lg/rnl) proteins and Freez-thaw (FT) Leishmania proteins (10 ).lg/ml) as coating antigens .
Cytokine assay
Two rnice from each group were scarificed before, 3 and 6 weeks after challenge and spleens were homogenized. After Iysis using ACK buffer, splenocytes were washed and re-suspended in complete RPMI medium . Cells were then seeded at a density of 2 x 10 6 cells/ml in the presence of I 0 ).lg/ml rE7, rE7 + rNT, rE7 + rCT, Freezthaw transgenic parasites as a recall antigen (provided in Molecular Immunology and Vaccine Research Lab.) and medium alone (RPMI 10%). Concanavalin A (ConA: 5 ).lg/ml) was also used as the positive control. Plates were incubated for 3 days at 37 oc in 5% C0 2 humidified atmosphere. Culture supe~n.atants from stimulated splenocytes under the same cond1t1ons were colle.cted in triplicate and assayed for IFN-r and IL~4 by a sandw1ch ELISA (R & D, Minneapolis, MN), accordmg to the manufacturer's instructions. The Iower detecti?n Iimits of IFN-r and IL-4 were 2 and 7 pg/ml, respect1vely.
ln vivo tumor protection
Three weeks after the second Vaccination mice were challenged subcutaneously with 1 x 105 TC~ 1 cellslmice.
All mice were followed for 50 days to monitor tumor ~rogres~ion. Tumor growth was determined by direct palpatlon t~lce a week. At each time point, tumor size was d~termm~d by measuring the srnallest diameter (a) and the b1~gest d1ameter (b) by caliper. Tumor volume was calculated usmg the formula: V= (a2b)/2 (Li et al., 2006 ) .
Statistical analysis
Statistical analysis was performed using Prism S.O software (GraphPad, San Diego, CA . .
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3 weeks after challenge with TC-I (p < 0.05), confirming the induction of Th I response (Figure 2 ). It is worth to mention that IFN-y immune responses were reduced gradually in G 1 and 02 after challenge, but were significantly comparable with other groups. The peak response in GI and G2 was elicited at 3 weeks after second immunization. Splenocytes from test groups (GI and G2) didn't elicit IL-4 production in comparison with control groups (p>0.05).
1788 b ti -protems effictently, the 2034 bp and were P 1 ragments encoding the E7-NT-GFP and E7-CT-GFP c on d · plasrn·d e tnto pLEXSY-neo2. Then, the recombinant lineart s Were prepared in Jarge scale with high purity, lllant zed and electroporated into parasites. The transforo418s were sel~cted by platingonsolid medium containing reco~b!ntegratton of genes in the genomic DNA of the 
Monitoring of E7-NT-GFP or E7-CT-GFP expression in L. tarentolae as a live vector
The expression of E7-NT-GFP and E7-CT-GFP using GFP Was monitored by Epi-fluorescent microscopy and flow cytometry. The expression of genes was readily evident from the intense green fluorescence of the parasites. Fluorescence-activated cell sorting (FACS) analysis indicated a clear quantitative separation between transfeered and wild type parasites (Figure 1 ). E7-NT-GFP and E7-Cf-OFP expression in transgenic L. tarenrolae were almost similar to GFP expression in Ltar-GFP at promastigote form (94% and 92.9% versus 97.5%, respectively). The stability of protein expression was monitored over a period of 3 months post-electroporation. There was no decrease in fluorescence intensity during this period in the absence of G4l8. Prolein expression was also detectable in cell extracts of transgenic parasites compared to wild type by weslern blotting. As shown in Figure J , the dominant bands of -81 and "'72 kDa detected in transgenic parasites expressing E7-NT-GFP and E7-Cf-GFP, respectively. No such corresponding bands were revealed in the wild-type promastigotes.
lmmunization with L.tar-E7-NT-GFP and L.tar-E7-CT-
GFP induces an IFN-gamma response in C57Bl/6 mice Protection following successful immunization requires the generation and maintenance of antigen-specific CD4+ Th cells. Herein, the Ievels of IFN-y and IL-4 were compared between different groups. Our results indicated a significant increase in the Ievel of IFN-y following stimulation with recall antigens, in all test groups as compared to unstimulated splenocytes. In addition, splenocytes from test groups (Gl-G3) produced significantly higher Ievels of IFN-y, before and after challenge as compared to control mice (G4, G5) (p < 0.05). However, the Ievels of IFN-y in G 1 and G2 were significantly higher than those in G3, before and Jmmunization with transgenic L. torento/ae elicits high Ievei of lgG2a after TC-1 challenge We evaluated the Ievels oflgGI and Jg02a antibodies against different antigens using ELISA before and 2 weeks after challenge. As shown in Figure 3 , 1gG2a Ievels were significantJy higher in test groups than those in control groups (p < 0.05). Interestingly, the Ievels of JgG I did not increase in test groups compared to Ltar-GFP (G4), before and after TCI challenge (data not shown).
Vaccination with L.tar-E7-CT {gp96)-GFP reduced significantly tumor growth after TC-1 challenge
Considering that L tarentolae is capable of eliciting a Th Itype cytokine response in mice, we tested whether vaccination with this vector expressing HPV16 E7-NT and E7-CT could protecl mice against I x 10 5 cell/ml TC-I tumors. C57BU6 mice immunized with Ltar-E1-CT-GFP (GJ) indicated considerably more protection than control groups even after 50 days (p < 0.05). Control groups (G4 and 05) and also Nai"ve mice developed progressive tumor growth. Our results indicated that group vaccinated with Ltar-E7-CT-GFP has significant protection compared to group vaccinated with Ltar-E7-GFP from 41 days afler TC-I challenge (1'<0.05) but not against group vaccinated with Ltar-E7-NT-GFP (p>0.05) (Figure 4 ).1n addition, group vaccinated with Ltar-E7-NT-GFP did not show any significanl protection in comparison with groups vaccinated with Ltar-E7-GFP (03) and Ltar-GFP (G4) after TC-I challenge (p > 0.05).
Discusslon
In current study, we evaluated the potency of live vaccines expressing HPVJ6 tumor antigen (E7) linked to N-/C-terminal fragments of gp96 as an adjuvant. Regarding to studies, the majority of clinical trials using therapeutic agents have shown limited efficacy in eradicating established tu mors in humans (Kanodia et al., 2008) . The design of recent clinical trials may have improved to examine efficacy of therapy in patients with early stage cancers when their immune system is more competent. Thus, the necessity to focus efforts on the development of new therapeutic strategies remains. Live recombinant vaccines that express HPV E7 or E6 proteins have proven generally to stimulate strong CD4+ and CD8+ T cell responses in mice model (Lin et al., 2010) . Various bacterial vectors have been explored in HPV therapeutic vaccines including listeria monocytogenes (Sewell et al., 2008) , Lactobacillus lactis (BermudezHumaran et al., 2005) , Lnctobacil/us plantarum (CortesPerez et al., 2005) and Salmonella (Krul et al., 1996) . Moreover, some effective properties make viral vectors a 
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)I -- ..... (A) Drug Deliv, 2013; 20(3-4): 190-198 a:ll Gl:l-tu-1:1-Cf (ep96) ß2 G2:l-lllr-I:7-:0.'T (ep96) e;:;J G3:l-lllr-E1 mD G4: l-t-.GTP Figure 3 . Before (A) and 2 weeks (B) after challenge, mice were bled and the pooled sera from each group were used to determine antibody Ievels against different antigens by ELISA. Data represcnt means ±SO and each assay was performcd in duplicate. p Values <0.05 have indicated statistically significant differences bctween GI/G2 and G3 vaccinated mice. feasible option in therapeutic HPV vaccines (Lin et al., 2010) . The Viruses include adenovirus (Gomez-Gutierrez et al., 2007 ), adeno-associated virus (Jin et al., 2005 , vaccinia virus (Lamikanra et al., 2001 ) and a/phaviruses (Cassetti et al., 2004) . The tumor cells may express different Ievels of antigenic peptides loaded by class I MHC molecule. For example, a portion of TC-I tumor cells may Ioad either E6-or E7-derived antigenic peptides on their MHC class I molecule in vivo (Held et al., 2008) . Thus, it is likely that some TC-I tumor cells may not be Jysed by CD8+ T cells generated from vaccination with a single antigen-encoding DNA vaccine, indicating the importance of broad immunity (Seo et al., 2009) . Furthermore, targeting the activation of DCs is an important strategy associated with the development of cancer vaccines since these cells play a central roJe in the induction of anti-tumor immunity (Seo et al., 2009) . In the present study, we investigated the potential of a non-pathogenic parasite, L tarento/ae (Basile & Peticca, 2009 ) against tumor as a live vaccine candidate vector to efficiently target DCs and lymphoid organs, thus enhancing antigen presentation and consequently influencing the magnitude and quality ofT cell immune responses. In addition, the fusion of antigen with heat shock proteins is one such strategy for enhancing immune responses and regression of HPV-16 E7-expressing tumors in mice (Devaraj et al., 2003) .. Herein, L tarentolae expressing E7-NT-GFP or E7-CT-GFP proteins were stably generated to immunize mice. We showed that the L tarento/ae expressing E7-Cf-GFP (GI) and also E7-NT-GFP (02) induce the production of IFN-y, thus skewing CD4+ T cells toward a Thl cell phenotype and acting as an immunostimulatory adjuvant. These recombinant strains successfully generated significant Ievels of lgG2a compared to other groups before and after challenge with TC-1 tumor cells. A significant protection Ievel of live Ltar-E7-CT-GFP was observed against the tumor outgrowth in comparison with live Ltar-E7 and control groups from 41 days after TC-I challenge but not against group vaccinated with Ltar-E7-NT-GFP. Regarding to the same IFN-gamma response in both Ltar-E7-CT-GFP and Ltar-E1-NT-GFP groups against Ltar-E1 antigen; thus, the protection observed in mice immunized with Ltar-E1-Cf-GFP through s.c. route could probably be attributed to other cytokines-secreting T cells toward a Th I cell phenotype. It is clear that s.c. administration is among the most applicable means of vaccine delivery in human (Ravindran et al., 2012) .
A study showed that the recombinant L tarentolae elicits an HIV-specific T-cell-mediated immunity (Barouch et al., 2003) , which makes it an attractive candidate not only against HIV-1 (Breton et al., 2007) , but also against other intracel1ular pathogens such as Leishmania infantum (Mizbani et al., 2009) . Recently, a recombinant non-pathogenic clone of Trypanosoma cruzi expressing a cancer testis antigen (NY-ES0-1) has been used as a vaccine vector to induce Jong-term T cell-mediated immunity and delay the rate of tumor development in mice (Junqueira et al., 2011) .
Some groups isolated molecular chaperones (Gp96 and Hsp90) as tumor-specific transplantation antigens, which provoked a highly specific immune response against a certain type of tumor (Robert, 2003; . Gp96 exerts adjuvant activity with some viral and bacterial antigens when applied in the form of a DNA vaccine . Some sturlies have shown the adjuvant activity of the N-/C-terminal domains of gp96 in DNA or protein vaccine strategies.
For instance, fusion of the C-terminal domain to Her2/neu inhibited the tumor growth (Pakravan et al., 2010) . Moreover, the N-terminal domain has also potent adjuvant activity toward hepatitis B surface antigen (Yan et al., 2007) . The . controversy surrounding adjuvant activity of these termmal domains of gp96 prompted us to compare their adjuvant activity toward HPV16 E7, as live vaccine in tumor mice model. In summary, this study showed the potential value of live Ltar-E7-CT-GFP vaccine that is successful in eliciting the proper immune responses and further proteelive effects. However, this formulation could not confer full protection against tumor challenge after 50 days. Two reasons could be assumed: (I) failure of the immune system at the final stages or (2) antigen loss and tumor escape (He et al., 2005; Kmieciak et al., 2007) . Thus, further studies are required to generate more potent live vaccine candidate and long-lived proteelive immunity against tumors using immuno-adjuvants.
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